Literature DB >> 2475184

Sequential loss of CD34 and class II MHC antigens on purified cord blood hematopoietic progenitors cultured with IL-3: characterization of CD34-, HLA-DR+ cells.

C Caux1, C Favre, S Saeland, V Duvert, P Mannoni, I Durand, J P Aubry, J E de Vries.   

Abstract

The expression of class II MHC and CD34 antigens on human cord blood hematopoietic progenitor cells (HPC) was investigated upon culturing in the presence of interleukin-3 (IL-3). HPC isolated by "panning" according to their expression of CD34 coexpressed HLA-DR and HLA-DP, and the majority of the CD34+ HPC also expressed HLA-DQ. In the presence of IL-3, the expression of CD34 and class II MHC antigens was found to be gradually lost in culture. Loss of CD34 expression preceded loss of HLA-DR expression. After eight days of culture, CD34-, HLA-DR+ blast cells were obtained that strongly proliferated in response to IL-3, GM-CSF, G-CSF, and M-CSF, and that had the capacity to generate macrophage and granulocyte colonies. After ten days of culture in IL-3, a population of CD34- cells that expressed low levels of HLA-DR (HLA-DRlo) was obtained by FACS-sorting. These CD34-, HLA-DRlo cells lacked colony-forming activity while the population expressing high levels of HLA-DR (HLA-DRhi) contained great numbers of colony-forming cells, and proliferated stronger in response to CSFs than the HLA-DRlo fraction. Finally CD34-, HLA-DR- cells that appeared later in the cultures (14 to 16 days) represented more differentiated cells with only marginal proliferative and no clonogenic capacity. These data indicate that whereas CD34 expression is associated with the multilineage potential of the HPC, HLA-DR expression correlates with overall proliferative capacity of hematopoietic cells during culture in IL-3.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475184

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Recovery kinetics after chemotherapy and circulating mononuclear cells expressing the CD34 antigen in pediatric cancer patients.

Authors:  W Emminger; G Fritsch; W Emminger-Schmidmeier; P Buchinger; D Printz; M Kundi; H Gadner
Journal:  Ann Hematol       Date:  1992-04       Impact factor: 3.673

Review 2.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

3.  A cellular model for drug interactions on hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis.

Authors:  M C Léglise; P Darodes de Tailly; J L Vignot; M A Le Bot; A M Le Roux; C Riché
Journal:  Cell Biol Toxicol       Date:  1996-02       Impact factor: 6.691

4.  Human cytomegalovirus plasmid-based amplicon vector system for gene therapy.

Authors:  Kutubuddin Mahmood; Mark N Prichard; Gregory M Duke; George W Kemble; Richard R Spaete
Journal:  Genet Vaccines Ther       Date:  2005-01-26

5.  Restoration of aged hematopoietic cells by their young counterparts through instructive microvesicles release.

Authors:  Steven J Greco; Seda Ayer; Khadidiatou Guiro; Garima Sinha; Robert J Donnelly; Markos H El-Far; Lauren S Sherman; Yannick Kenfack; Sri Harika Pamarthi; Marina Gergues; Oleta A Sandiford; Michael J Schonning; Jean-Pierre Etchegaray; Pranela Rameshwar
Journal:  Aging (Albany NY)       Date:  2021-11-11       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.